Till 2020 Singapore will be the host for the next three editions of the leading breast cancer summit of the Asia Pacific region
Singapore - Tuesday, September 29th 2015 [ME NewsWire]
MCI is proud to announce the fifth edition of the Asia Pacific Breast Cancer Summit (APBCS) will be held in Singapore from 27 – 28 February 2016. At the summit, educational leaders and delegates will come together and share their knowledge to further the research and development of breast cancer treatment.
With the support of the Singapore Exhibitions and Conventions Bureau (SECB), the APBCS will be held in Singapore for three consecutive editions – 2016, 2018 and 2020.
The 2016 summit will be chaired by some of the best minds in the field like Drs. Rebecca Dent (Senior consultant in National Cancer Centre Singapore’s division of medical oncology), Paul Mainwaring (Consultant Medical Oncologist at Australia’s ICON Cancer Care) and Shaheenah Dawood (Head of medical oncology and breast cancer programme at Dubai Hospital). The summit will aim to drive meaningful discussions – ranging from breast cancer management to aspects of clinical care such as surgery, radiation and oncology.
Breast cancer is one of the most common cancers in women in both developed and underdeveloped nations of the world, and there is a need to discuss the latest developments of the condition and its alarming increase. For the last four years, the APBCS has been addressing vital topics regarding this prevalent disease and will explore the vast array of molecular technologies, imaging and treatments, including how to apply them to patients.
Mr Ajay Bhojwani, Managing Director MCI Middle East commented: “APBCS is the most important congress of oncology in the Asia Pacific Region focusing on the research and developments in breast cancer. Research in oncology has become a global approach and APBCS provides the perfect educational platform for oncologists from all over the world to converge in beautiful Singapore and interact with leading experts.”
Asia-Pacific is the world's most important market for oncology drugs. In a report published in February this year, market research firm Frost & Sullivan valued the global oncology drugs market at US$91 billion, a market that is expected to reach US$111.9 billion by 2020.
Added Ms Jeannie Lim, Executive Director (Conventions, Meetings and Incentive Travel), SECB: “We are delighted that MCI has decided to bring the next three editions of APBCS to Singapore. Singapore has a vibrant medical and scientific ecosystem which boasts the presence of the world's top research and development, biotech and medical companies. Thus, the knowledge shared at the APBCS will certainly enrich the regional oncology community and we look forward to breaking new ground together through this Summit. Beyond the summit, Singapore is also a vibrant destination that provides event attendees with rich multi-cultural experiences and a vast array of dining and retail options. I would like to extend a warm welcome to all APBCS attendees here, and invite them to enjoy all that Singapore has to offer.”
MCI is the world’s largest provider of strategic engagement and activation solutions and has been a key driver of innovation in the meetings, events, association and congress industries since 1987. Through creative live experiences and digitization, globalization, brand enhancement and content strategies, MCI helps multinational companies and international associations enhance organizational performance, grow globally, energize communities and drive business results. An independent, privately held company with headquarters in Geneva, Switzerland, MCI’s 1,800 professionals in 60 cities and 31 countries help clients across Europe, the Americas, Asia-Pacific, India, the Middle East and Africa unlock their potential and deliver real change. Find out more at www.mci-group.com.
MCI Middle East
+971 4 311 6300